Literature DB >> 6952949

Isolation of myeloid progenitor cells from peripheral blood of chronic myelogenous leukemia patients.

J D Griffin, R P Beveridge, S F Schlossman.   

Abstract

Myeloid progenitor cells (colony- and cluster-forming cells in semisolid medium, CFU-GM) were purified from the peripheral blood of chronic myelogenous leukemia (CML) patients. Lymphocytes, monocytes, and most immature myeloid cells were simultaneously depleted with specific monoclonal antibodies using an erythrocyte rosette technique for cell separation. Cells expressing Ia-like antigen were then selected from the residual cell population. Day 7 CFU-GM were enriched 44--116-fold in the IA+ cell fraction, when compared to the unseparated cells, and up to 47% of the cells could form a myeloid colony or cluster in culture. This cell fraction contained up to 92% undifferentiated blasts, with the remainder mostly promyelocytes. The enriched CFU-GM cells were dependent on an exogenous supply of colony-stimulating factor for growth, and colony formation was linear with cell concentration over a large range (10(4)-10(1) cells/ml). This technique of rosette depletion and enrichment with specific monoclonal antibodies provides a unique method for purifying a homogenous population of myeloid precursor cells with defined surface antigen characteristics.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6952949

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Monocyte heterogeneity in angiotensin-converting enzyme induction mediated by autologous T lymphocytes.

Authors:  J H Ryu; Z Vuk-Pavlović; M S Rohrbach
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

2.  Clonal analysis of CD4+/CD8+ T cells in a patient with aplastic anemia.

Authors:  U Moebius; F Herrmann; T Hercend; S C Meuer
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

3.  Genes encoding the T-cell receptor alpha and beta subunits are transcribed in an ordered manner during intrathymic ontogeny.

Authors:  H D Royer; D Ramarli; O Acuto; T J Campen; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

4.  Purification of human erythroid colony-forming units and demonstration of specific binding of erythropoietin.

Authors:  K Sawada; S B Krantz; J S Kans; E N Dessypris; S Sawyer; A D Glick; C I Civin
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

5.  Characterization of a human hematopoietic progenitor cell capable of forming blast cell containing colonies in vitro.

Authors:  J Brandt; N Baird; L Lu; E Srour; R Hoffman
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

6.  Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow.

Authors:  S Koizumi; G A Curt; R L Fine; J D Griffin; B A Chabner
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

7.  Declining sensitivity to interleukin 3 of murine multipotential hemopoietic progenitors during their development. Application to a culture system that favors blast cell colony formation.

Authors:  K Koike; J N Ihle; M Ogawa
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

8.  Purification of fetal hematopoietic progenitors and demonstration of recombinant multipotential colony-stimulating activity.

Authors:  S G Emerson; C A Sieff; E A Wang; G G Wong; S C Clark; D G Nathan
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

Review 9.  Characterization of hematopoietic stem and progenitor cells.

Authors:  D E Williams; L Lu; H E Broxmeyer
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

10.  B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation.

Authors:  L M Nadler; S J Korsmeyer; K C Anderson; A W Boyd; B Slaughenhoupt; E Park; J Jensen; F Coral; R J Mayer; S E Sallan
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.